Clinical Trials Arena on MSN2d
Opthia could owe $1bn to investors amid sozinibercept trial failure
The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...
Benzinga.com6d
FDA Calendar
CEL-SCI Corporation announced new data has been published from its prior Phase 3 study of Multikine* (Leukocyte Interleukin, Injection) in newly diagnosed, treatment naïve, resectable, locally ...
Ophthalmology Times2d
Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edema
UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...
Yahoo Finance6d
Ocugen, Inc. (OCGN)
After hours: March 21 at 7:58:35 PM EDT Loading Chart for OCGN ...
Yahoo Finance3d
Ocugen, Inc. (OCGN)
After hours: 24 March at 7:59:43 pm GMT-4 Loading Chart for OCGN ...